Placebo News and Research

RSS

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers.

25 Sep 2014

Research findings open up new avenues for development of chronic itch treatments

Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.

25 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease.

22 Sep 2014

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy.

19 Sep 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

Discovery reveals promising target for treatment of end-stage heart failure

As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9th in the American Heart Association journal, Circulation.

10 Sep 2014

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection.

9 Sep 2014

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma.

9 Sep 2014

Placebo News and Research

NCCN ORP awards four research grants to advance development of nintedanib

Research findings open up new avenues for development of chronic itch treatments

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

Ramucirumab effective second-line option for NSCLC

LABA-ICS combination therapy better than LABAs alone for COPD

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

FDA approves Contrave extended-release tablets for chronic weight management

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Discovery reveals promising target for treatment of end-stage heart failure

Researchers examine whether new drug offers added benefit for patients with chronic HCV

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News